Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab in High-risk Patients With Atrial Fibrillation (LILAC-TIMI 76 OLE)
NCT07739888Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2027
- Primary completion
- Dec 2030
01
Overview
Phase 3, open-label, single-arm trial of abelacimab in Atrial fibrillation (AFib), sponsored by Novartis. Primary endpoints: Time to first ISTH major Bleeding events up to 3 years, Time to first BARC type 3c/5 bleeding up to 3 years and 5 more. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07739888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739888.